Skip to main content

Table 2 The characteristics of COPD patients at baseline.

From: Effects of inhaled corticosteroids on sputum cell counts in stable chronic obstructive pulmonary disease: a systematic review and a meta-analysis

Source

Number of Patients

Age (year)

Men (%)

Current Smokers (%)

Pack-years

FEV1 (% predicted)

Ratio (%)

Reversibility (% predicted)

Drug

Dose (mg/day)

Duration (weeks)

Cumulative dose (mg) #

Sugiura [7]

18‡

70(7)

89

0*

NR

1.2(0.4)†

<70

<12

Beclomethasone

0.8

4

22.4

Keatings [18]

26

45–78

60

46

>10

35.1(4.7)

<70

<10

Budesonide

1.6

2

28.0

Culpitt [19]

26

43–73

62

69

>20

49.5(16.6)

<70

<15

Fluticasone

1.0

4

56.0

Confalonieri [20]

34

58 (5)

59

100

NR

59.7(37.1)

67 (5)

NR

Beclomethasone

1.5

8

84.0

Mirici [21]

40

53(10)

75

100

26.5 (16.1)

62.0(7.4)

NR

<15

Budesonide

0.8

12

84.0

Yildiz [22]

18

64(7)

78

89

52.0 (23.4)

44.5(2.7)

57 (3)

<10

Fluticasone

1.5

8

168.0

  1. † FEV1, liter;
  2. ‡ 6 patients in control group
  3. * All subjects were ex-smokers and stopped smoking for at least 1 year.
  4. # Cumulative dose = daily dose × days × adjusted factor for beclomethasone equivalence [14].
  5. Continuous variables are presented as mean (SD)
  6. Abbreviations: FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; ratio, the ratio of FEV1 to FVC; NR, not reported/not calculable.